WEST HARRISON, NY/ ACCESSWIRE/ September 1, 2015/ The continuing progress of CEL-SCI Corporation, arguably the most undervalued Phase III biotech company, is profiled in the August 27th issue of Flaherty Financial Newsletter #50. 2017 is the expected date for the overall survival readout of this very important $50 million, 24 countries global Phase
Aequus Pharmaceuticals reported its stock is now trading on the OTCQB Venture Market in the United States under the symbol "AQSZF." Aequus will continue to trade on the Toronto Venture Exchange under its existing symbol "AQS". Aequus Pharmaceuticals is a Vancouver- based, specialty pharmaceutical company primarily focused on developing and commerci
PARIS- Agile Therapeutics Inc. has completed patient recruitment in its phase III clinical trial of Twirla, its investigational contraceptive patch. Aimmune Therapeutics Inc. plans to initiate an international phase III registrational trial of AR101 in children and adults with peanut allergy in early 2016.. Peanut allergy is a serious and growing h
Allergan acquired Naurex for a $560 million upfront payment net of cash acquired, $460 million of which is payable upon the closing of the acquisition and $100 million of which is payable by January of 2016, as well as potential R&D success-based and sales-threshold milestone payments. This is an area of medicine that requires new ways to tackle so
Release date- 31082015- ALBANY, N.Y.- AMRI and Saneca Pharmaceuticals, a.s. today announced a strategic collaboration focused on the development, manufacture and marketing of a portfolio of opium-derived active pharmaceutical ingredients. Based on customer demand, AMRI will prepare the U.S. regulatory filings, and following FDA approval, will manuf
BioTime reported that BioTime management will present at the Rodman& Renshaw 17th Annual Investment Conference in New York City from 3 to 3:25 p.m. EDT on Thursday, September 10. According to a release, investors will receive an update on BioTime and its subsidiaries. BioTime, a provider of regenerative medicine, is a clinical- stage biotechnology
ELSTREE, England& DURHAM, N.C. Bio Products Laboratory, Limited, a leading manufacturer of plasma-derived protein therapies, today announced that the first subject has enrolled in SCIG03, a clinical trial evaluating the safety and pharmacokinetics of Subgam VF, 16% liquid immunoglobulin for the treatment of primary immunodeficiency.
The deal gives Bristol-Myers access to Promedior's lead experimental drug, PRM-151, which is being tested to treat two types of fibrosis. Promedior's mid-stage studies of its fibrosis drug are expected to begin in the next few weeks, Bristol-Myers said yesterday. Massachusetts- based Promedior is backed by healthcare investors including British dru
Celator Pharmaceuticals, Inc., a biopharmaceutical company that is transforming the science of combination therapy and developing products to improve patient outcomes in cancer, today announced that Scott Jackson, Chief Executive Officer, will present an overview of the company at the Rodman& Renshaw 17 th Annual Global Investment Conference in N
BeyondSpring Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on the development of innovative cancer therapies, today announced the presentation of an investigator initiated study supporting its lead compound, Plinabulin, at the upcoming 16 th World Conference on Lung Cancer, which is hosted by the International Associat
DGAP-News: Neovacs S.A./ Key word: Study NEOVACS RECEIVES FIRST REGULATORY APPROVALS FOR A PHASE IIb TRIAL OF IFN-KINOID IN LUPUS 01.09. 2015/ 08:00- PRESS RELEASE NEOVACS RECEIVES FIRST REGULATORY APPROVALS FOR A PHASE IIb TRIAL OF IFN-KINOID IN LUPUS IFN-K-002 clinical trial
Egalet Corporation, a fully integrated specialty pharmaceutical company focused on discovering, developing, and commercializing innovative pain treatments, today announced that researchers will be presenting scientific data on SPRIX Nasal Spray, Egalet -001, an abuse-deterrent, extended-release, oral morphine product candidate, and Egalet -002
Eleven Biotherapeutics, Inc., a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, announced the promotions of Gary Sternberg, MD, MBA, to Chief Business Officer and John McCabe, CPA, to Senior Vice President, Finance. Gary and John have demonstrated strong leadership and played
Eyegate Pharmaceuticals, Inc., a specialty pharmaceutical company that focuses on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye, today announced Stephen From, President& Chief Executive Officer of EyeGate is scheduled to present at the 17 th Annual Rodman& Renshaw Global Investment conferen
Research and Markets has announced the addition of the "FDA Drug Approval Process" conference to their offering. This seminar, by a US lawyer with over 40 years of experience dealing with pharmaceutical regulation in the United States and Europe, will provide a general introduction to all aspects of the US drug approval process. It will also cove
Forward Pharma A/S, a biopharmaceutical company working to advance a proprietary formulation of DMF for the treatment of inflammatory and neurological indications, today announced that Joel Sendek, the Company's Chief Financial Officer, will participate in the following conferences:. FBR's Second Annual Healthcare 1- on-1 Conference to be held at
Heat Biologics, Inc., a clinical stage cancer immunotherapy company, announced that it has enrolled the first patient in a Phase 1 b clinical trial investigating the combination of its HS-110 therapeutic vaccine and the Bristol-Myers Squibb PD-1 inhibitor nivolumab in non-small cell lung cancer. Additionally, as the FDA approval of nivolumab and.
Last year, Duke University Press published "Speculative Markets: Drug Circuits and Derivative Life in Nigeria" by Kristin Peterson, who teaches at the University of California, Irvine. Using Idumota in Lagos as a focus of her research, she reveals how some multinational drug companies, driven essentially by profit motives, conspire with desperate d
Saniona announces its intention to list the company on Nasdaq Stockholm Small Cap in 2016 and appoints CFO Thomas Feldthus as executive vice president to head up the process. Results reported from preclinical development and disclosure of Phase 1 plans for AN363. University of Pennsylvania's Treatment Research Center is granted rights to perf
Release date- 31082015- Paris- Ipsen today announced that The Lancet Neurology has published online at http://www.thelancet.com/neurology the detailed results from the Ipsen sponsored phase III randomized study showing the efficacy and safety of Dysport in post-stroke or traumatic brain injury patients with upper limb spasticity.
Navitor Pharmaceuticals, Inc., a biopharmaceutical company developing novel medicines targeting the activation of mTORC1, today announced that pharmaceutical industry veteran David M. Madden, founder and principal with Narrow River Management, LP and chairman of the board of directors of Dicerna Pharmaceuticals, has joined the Navitor Board of...
Merck, known as MSD in the United States and Canada, today announced results from new analyses from the IMPROVE-IT study. Michael A. Blazing, Duke Department of Medicine. Merck has submitted the data from the IMPROVE-IT study to the U.S. Food and Drug Administration to support a new indication for reduction of cardiovascular events for ZETIA and VY
Otonomy, Inc., a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the ear, today announced the appointment of Ted Schroeder to its board of directors. Most recently, Mr. Schroeder led specialty pharmaceutical company Cadence Pharmaceuticals from its.
By a News Reporter-Staff News Editor at Life Science Weekly From Alexandria, Virginia, NewsRx journalists report that a patent by the inventors Buffa, Radovan; Kettou, Sofiane; Pospisilova, Lucie; Huerta-Angeles, Gloria; Chladkova, Drahomira; Velebny, Vladimir, filed on December 10, 2010, was published online on August 18, 2015. The patent's assi
TARRYTOWN, N.Y., and PARIS, Sept. 1, 2015/ PRNewswire/ Regeneron Pharmaceuticals, Inc. and Sanofi today announced that, in a new pooled analysis of heterozygous familial hypercholesterolemia patients included in the ODYSSEY clinical trial program, Praluent significantly reduced bad cholesterol, known as low-density lipoprotein cholesterol. 1 T